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Aurora A kinase and MEK inhibitors induce different, and potentially complementary,
effects on the cell cycle of malignant cells, suggesting a rational basis for utilizing these
agents in combination. In this work, the combination of an Aurora A kinase and MEK
inhibitor was evaluated in pre-clinical colorectal cancer models, with a focus on identifying
a subpopulation in which it might be most effective. Increased synergistic activity of the
drug combination was identified in colorectal cancer cell lines with concomitant KRAS
and PIK3CA mutations. Anti-proliferative effects were observed upon treatment of these
double-mutant cell lines with the drug combination, and tumor growth inhibition was
observed in double-mutant human tumor xenografts, though effects were variable within
this subset. Additional evaluation suggests that degree of G2/M delay and p53 mutation
status affect apoptotic activity induced by combination therapy with an Aurora A kinase
and MEK inhibitor in KRAS and PIK3CA mutant colorectal cancer. Overall, in vitro and
in vivo testing was unable to identify a subset of colorectal cancer that was consistently
responsive to the combination of a MEK and Aurora A kinase inhibitor.
Keywords: MEK, Aurora A kinase, colorectal cancer, human tumor xenografts, alisertib, trametinib, KRAS
mutation, PIK3CA
Introduction
With the advent of studies showing patients with KRAS exon 2 mutations (Amado et al., 2008;
Karapetis et al., 2008), and now extended RASmutations (KRAS exon 2, 3, 4, and NRAS exon 2, 3,
4) (Douillard et al., 2013; Heinemann et al., 2014), do not derive benefit from treatment with EFGR-
targeting monoclonal antibodies, the treatment paradigm for metastatic colorectal cancer (CRC)
is shifting to one focused on the molecular subsets of this malignancy. Not only do these studies
demonstrate an unmet need for therapy in patients with extended RASmutations, but also for those
patients with RAS wild-type (WT) CRC who do not respond to EGFR-inhibition. The possibility
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of other molecular subtypes of CRC that may be represented
within these unresponsive groups is of great interest, especially
in the development of novel therapies for this disease. Given
the lessons learned from the development of EGFR inhibitors
in metastatic CRC, there is a new focus on identification of
biomarkers predictive of response to novel agents early in their
development.
Aurora kinase inhibitors are a class of novel agents that disrupt
the normal functions of nuclear kinases Aurora A, B, and C in
spindle pole organization and mitosis leading to disruption of
cell division and chromosomal abnormalities (Lens et al., 2010;
Kollareddy et al., 2012). Aurora A kinase-selective inhibitors
are specifically known to induce transient mitotic arrest, with
the goal of inducing apoptotic cell death in mitosis (Hilton
and Shapiro, 2014). Clinical trials with these agents are still
in early phases, though no overwhelming single-agent activity
in colorectal cancer has yet been noted, and no biomarkers
predictive of response to therapy have been identified (Diamond
et al., 2011; Cervantes et al., 2012; Dees et al., 2012; Falchook et al.,
2014). However, the specific, targeted mechanism of Aurora A
kinase inhibitors makes their use in combination with an agent
that may enhance apoptotic activity in cancer cells that have
undergone abnormal mitotic progression one of great interest.
As KRASmutations occur in approximately 40% of colorectal
cancers (de Roock et al., 2010), various drugs targeting
downstream of RAS in the mitogen-activated protein kinase
(MAPK) pathway have been evaluated as potential therapies.
MEK inhibitors, which have achieved significant success in the
treatment of BRAF mutant melanoma (Flaherty et al., 2012),
have been less effective as single agents in early clinical trials
of both unselected (Bennouna et al., 2011) and KRAS mutant
colorectal cancer patients (Zimmer et al., 2014). Though the use
of MEK inhibitors as single-agent therapy in colorectal cancer is
not supported by these results, a recent phase II study of a MEK
inhibitor combined with irinotecan inKRASmutant CRC yielded
interesting results worthy of further study (Hochster et al., 2015).
This suggestion of combination activity in a subgroup of CRC, as
well as the known importance of theMAPK pathway in colorectal
cancer, supports evaluation of MEK inhibitors as part of rational
combination therapy with other novel agents.
Though the primary function of MAPK pathway inhibition is
to block signaling for cell growth and proliferation, interruption
of this pathway is also thought to affect cell cycle progression at
G1 (Pages et al., 1993). In addition, it has been suggested that
inhibition of MEK as an effector of the MAPK pathway affects
the function of the cellular DNA damage response (Wei et al.,
2011). It was thus hypothesized that adding a MEK inhibitor to
an Aurora A kinase inhibitor, which may induce DNA damage
through induction of defects in mitotic progression (Perez de
Castro et al., 2013) and differentially target the cell cycle at
G2/M phase (Hirota et al., 2003), may protect the genomic
instability induced by the Aurora A kinase inhibitor from
cell cycle check points and DNA damage response, ultimately
facilitating cancer cell death (Collins et al., 2012). This hypothesis
has been further supported by the concept that sustained cell
cycle arrest (facilitated in this case by the combination of
Aurora A kinase and MEK inhibition) allows for more consistent
initiation of apoptosis and ultimately cell death (Hilton and
Shapiro, 2014). The importance of the MAPK pathway in CRC,
as well as the limited single-agent activity of MEK inhibitors in
this tumor type, provide an ideal setting for evaluation of this
hypothesis.
A recent study of Aurora A kinase inhibitor MLN8054, MEK
inhibitor trametinib, and BRAF inhibitor dabrafenib evaluated
various combinations of these drugs in BRAF mutant melanoma
cell lines (Caputo et al., 2014). Of particular interest in this
study were the more pronounced anti-proliferative effects of
MLN8054 and trametinib as compared to the combination of
trametinib and dabrafenib, a drug combination recently shown to
improve progression free survival in patients with BRAF mutant
melanoma (Long et al., 2014). Though observed in a different
tumor type, the anti-proliferative effects of the combination of
an Aurora A kinase inhibitor and MEK inhibitor demonstrated
in this study do support further investigation of this novel
combination.
The goal of this study was to evaluate the efficacy of the
combination of an Aurora A kinase inhibitor and MEK inhibitor
in colorectal cancer models, with an early focus on identification
of a molecular subgroup of CRC more likely to benefit from such
therapy.
Materials and Methods
Reagents
Investigational Aurora A kinase inhibitor alisertib and
MEK inhibitor TAK-733 were provided by Millennium
Pharmaceuticals, and MEK inhibitor trametinib was purchased
from Selleck Chemicals. For in vitro work all agents were
dissolved in 100% DMSO at a concentration of 10mM. For
in vivo work, alisertib was suspended in a half volume of 20%
2-hydroxypropyl-β-cyclodextrin in sterile water (w/v) and then
diluted with a solution of 2% sodium bicarbonate in sterile water
(w/v) to provide a final formulation in 10% 2-hydroxypropyl-β-
cyclodextrin / 1% sodium bicarbonate, TAK-733 was suspended
in 0.5% methylcellulose, and trametinib was suspended in 10%
Cremophor EL/10% PEG 400 in water.
Cell Lines and Culture
The human colorectal cancer cell lines HCT116, DLD-1, LS174T,
LS180, HCT-15, SW948, T84, Mip101, were obtained from
American Type Culture Collection and SNU1544 was obtained
from the Korean Cell Line Bank, and identities were confirmed
by DNA profiling at the University of Colorado Cancer Center
DNA Sequencing and Analysis Core. Cells were cultured in
Roswell Park Memorial Institute (RPMI) media, supplemented
with 10% FBS (Invitrogen), 1% nonessential amino acids (Cellgro
Mediatech), 1% penicillin/streptomycin, and 0.1% puromycin.
Cells were maintained in an incubator at 37◦ in 5% CO2.
Evaluation of Cellular Proliferation
Sulforhodamine B (SRB) assay was used to evaluate proliferation
of cells treated with TAK-733 and alisertib as single agents and
in combination. Cells plated in tissue-treated 96-well plates were
exposed to concentrations of single-agent TAK-733 increasing
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from 0 to 0.25µM and to single-agent alisertib increasing from 0
to 0.5µM.At 72 h cells were fixed with trichloroacetic acid (TCA)
and stained with 0.4% SRB (MP biomedicals), with staining
intensity quantified at an absorbance wavelength of 525 nM
(Biotek Synergy 2). Cell lines were also exposed to combination
therapy with TAK-733 and alisertib at the following doses: 0,
0.0625, 0.125, and 0.25µM of TAK-733 and 0, 0.03125, 0.125,
and 0.5µM of alisertib. Proliferation evaluation was performed
at 72 h by SRB assay as described above. The combination
was evaluated for synergy using the Chou and Talalay method
(CalcuSyn), with a CI value >1 consistent with antagonism, a CI
value equal to 1 indicating additivity, and a CI value<1 indicative
of synergy.
Immunoblotting
Immunoblotting was performed on HCT116, DLD-1, LS180, and
LS174T cell lines. Cells were seeded in 6-well plates and then
treated with no drug, 0.125µM alisertib, 0.125µM TAK-733, or
the drug combination at time points ranging from 24 to 72 h.
At completion of drug exposure, media was aspirated and cells
washed with 1X PBS. Radioimmunoprecipitation assay (RIPA)
lysis buffer with Halt protease/phosphatase inhibitor cocktail
(Thermo) was added for cell lysis, and protein quantified with use
of Thermo Pierce 660 nm Protein Assay Reagent. Protein was run
on 4–12% gradient Bis-Tris NuPAGE gels (Life Technologies)
and transferred to nitrocellulose using the i-Blot system (Life
Technologies). Primary antibodies used for immunoblot analysis
include ERK, pERK, AKT, pAKT, Cyclin B1, pCyclin B1, PARP,
Cleaved PARP, p53, p73, p21, pAurora A, pHH3, β-actin and
α-tubulin (Cell Signaling Technology). Incubation with goat
anti-mouse and goat anti-rabbit secondary antibodies (LI-COR
Biosciences) followed. Blots were developed using the Odyssey
Infrared Imaging System (LI-COR Biosciences).
For immunoblot analysis of phosphorylated Aurora A kinase,
pre-treatment of cells with nocodazole was used to induce G2/M
phase arrest. Cells were treated with nocodazole 0.5µg/mL
for 18 h, followed by a 2-h exposure to media without drug
or with alisertib at a dose of 0.03125, 0.0625, or 0.125µM.
Immunoblotting was performed as above.
Cell Cycle Analysis
Cell suspension containing 250,000 cells per well of HCT116,
DLD-1, LS174T and LS180 was plated in 6-well plates for
overnight incubation, and then treated with no drug, 0.125µM
alisertib, 0.125µM TAK-733, or the combination for 24 h. Cells
were then washed with 1X PBS and resuspended in Krishan’s
stain and incubated for 24 h at 4◦C prior to flow cytometry. They
were next analyzed by flow cytometry for cell cycle status by
the University of Colorado Cancer Center Flow Cytometry Core
Facility using an FC500 flow cytometer.
Caspase 3/7 Assay
DLD-1 and LS174T cell suspensions were plated in volumes
of 100µL into tissue-treated 96-well plates for overnight
incubation. Cells were then exposed to 0, 0.03125, 0.125, or
0.5µM of alisertib and 0, 0.0625, 0.125, or 0.25µM of TAK-
733 for 24, 48, or 72 h. A volume of 100µL of Caspase-Glo 3/7
reagent was then added for incubation at room temperature for
1 h. Luminescence was then measured on a plate reader (Biotek
Synergy 2) with normalization to the control group.
Cell Line Xenograft Models
Female athymic nude (nu/nu) mice were purchased from the
Harlan Labs at age 4–6 weeks. Mice were allowed to acclimate
for a minimum 7 days, and then caged in groups of 5 and
kept on a 12-h light/dark cycle. They were provided sterilized
food and water ad libitum. At logarithmic phase of growth,
colon cancer cell lines HCT116, HCT15 and COLO741 were
harvested. Cells were resuspended in a 1:1 mixture of serum-
free RPMI media and Matrigel (BD Biosciences), and 2.5 ×
106 cells in a volume of 100µL were injected into the right
and left flank. Tumor sizes were monitored three times per
week by caliper measurements with the Study Director Program,
and tumor volumes calculated using the following formula:
volume = (length × width2) × 0.52. Xenograft mice from each
cell line were randomized into 4 groups once tumors reached
150–300mm3: vehicle control, alisertib 3mg/kg daily, TAK-733
3mg/kg daily, or alisertib 3mg/kg daily and TAK-733 3mg/kg
daily in combination. All drugs were administered via oral
gavage. At the end of treatment (22 days for HCT116, 17 days for
HCT15, and 29 days for COLO741), mice were euthanized with
CO2 followed by cervical dislocation and tumor samples were
collected. Animal studies were performed in a facility accredited
by the American Association for Accreditation of Laboratory
Animal Care in accordance with the NIH guidelines for care
and use of laboratory animals and approved by the University of
Colorado Institutional Animal Care and Use Committee (Permit
number 51413(06)1E) prior to initiation.
In vivo Combination Modeling
Tumors were modeled individually, with average model fits
created from the mean of each individual fit, as previously
described (Koch et al., 2009; Bradshaw-Pierce et al., 2013). Based
on this modeling, a mathematical assessment of synergistic,
additive, or antagonistic response to combination therapy was
assessed. Themathematical termψwas identified for eachmodel,
where ψ > 1.3 demonstrates a synergistic effect, ψ between
0.7 and 1.3 is consistent with additive effect, ψ between 0.7 and
0 is less than additive, and ψ < 0 is antagonistic. Additional
modeling details can be found in the Supplemental Data Sheet 1.
Patient-Derived Tumor Xenograft Models
Tumor specimens were collected from consenting patients at the
University of Colorado Hospital at the time of surgery. Tumor
tissue remaining after histopathologic analysis was cut into 2–
3mm3 pieces and submerged in Matrigel. Female athymic nude
mice were acquired and cared for as described above. After
a minimum of 1 week, 12 gauge trocars were used to inject
tumor sections subcutaneously into the bilateral flanks of each
mouse. Tumor sizes were monitored three times per week by
caliper measurements as described above. Mice were randomized
into 9 groups once tumors reached 150–300mm3. These groups
were then treated with vehicle control, alisertib 10mg/kg daily,
alisertib 20mg/kg daily, trametinib 0.5mg/kg daily, trametinib
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1.5mg/kg daily, or combination therapy with alisertib 10mg/kg
and trametinib 0.5mg/kg daily, alisertib 10mg/kg and trametinib
1.5mg/kg daily, alisertib 20mg/kg and trametinib 0.5mg/kg
daily, or alisertib 20mg/kg and trametinib 1.5mg/kg daily, all
administered via oral gavage. After 32 days of treatment, mice
were euthanized with CO2 and tumor samples were collected.
As above, animal studies were performed in a facility accredited
by the American Association for Accreditation of Laboratory
Animal Care in accordance with the NIH guidelines for care
and use of laboratory animals and approved by the University of
Colorado Institutional Animal Care and Use Committee (Permit
number 51413(06)1E) prior to initiation.
Statistical Analyses
A nonparametric Kruskal-Walls test with a Dunns post-
test was used to determine statistical significance between
multiple groups. An unpaired t-test with two-tailed p-values
and 95% confidence interval was used to determine statistical
significance between two groups. Analyses were performed
with Prism version 5.0, p < 0.05 was considered statistically
significant.
Results
In vitro Effects of Combination Therapy with
Aurora A Kinase and Mek Inhibitors
Effects of Alisertib and TAK-733 Alone and in
Combination on Proliferation of Colorectal Cancer
Cell Lines
Anti-proliferative effects of the combination of the
investigational Aurora A kinase inhibitor alisertib and the
MEK inhibitor TAK-733 were evaluated by SRB in cell
lines representing 4 distinct molecular subtypes of CRC:
KRAS/PIK3CA mutant (MT), KRAS MT/PIK3CA WT, KRAS
WT/PIK3CA WT, and BRAF MT. Synergy was evaluated using
the Chou and Talalay method (Chou and Talalay, 1984) in four
cell lines from each molecular subtype; HCT116, HCT-15, Mip-
101, and LS180 for KRAS/PIK3CA MT; GP5d, SW620, CL-11,
and LoVo for KRAS MT/PIK3CA WT; HT55, HT15, SNU-1235,
and SW48 for KRAS WT/PIK3CA WT; and COLO741, MDST8,
HT-29, and RKO for BRAF MT. Average combination index
(CI) values were compared between molecular subtypes. A CI
value of <1 is consistent with a synergistic drug effect, while
a CI value >1 is consistent with an antagonistic drug effect,
and a CI value equal to 1 demonstrates an additive effect of
the combination. A more pronounced synergistic effect was
observed in the KRAS/PIK3CA MT (double-mutant) CRC cell
lines, with a mean CI value of 0.55 ± 0.05, as compared to
53.68 ± 5.48 in the KRASMT/PIK3CAWT model, 0.89 ± 0.097
in the KRAS WT/PIK3CA WT model, and 0.876 ± 0.077 in the
BRAF MT model (Figure 1A). Based on these observations, the
KRAS/PIK3CA MT molecular subtype was identified as one of
particular interest in the evaluation of alisertib and TAK-733,
and a total of nine double-mutant colorectal cancer cell lines
were selected for further assessment (Figure 1B).
The nine additional CRC cell lines were exposed to each drug
as a single agent, and proliferation was assessed to determine
single-agent activity (Figure 1C). The HCT116, LS174T, and
T84 cell lines were most sensitive to alisertib as a single
agent, with calculated IC50 values of 0.04, 0.05, and 0.09µM,
respectively, while the LS180, LS174T, HCT116, and SW948
cell lines were most sensitive to single-agent TAK-733, with
calculated IC50 values of 0.008, 0.033, 0.038, and 0.045µM.When
cells were exposed to the combination of alisertib and TAK-
733 for 72 h, growth inhibition was noted to increase beyond
that observed with either drug as a single-agent (data from
4 representative cell lines shown in Figure 1D). These effects
were most consistently demonstrated at the middle (0.125µM of
alisertib and TAK-733) and high (alisertib 0.5µM and TAK-733
0.25µM) concentrations of each drug, and the middle dose level
was selected for further investigation.
The effect of the drugs in combination was also evaluated
through application of the Chou and Talalay method (Flanigan
et al., 2013) to SRB proliferation data. Combination index
values were compared between cell lines in an effort to identify
subgroups within the double-mutant models in which synergistic
vs. antagonistic effects of the drug combination might be
identified. According to SRB data, a sub-additive response to
combination therapy was demonstrated in the LS180, SW948 and
SNU1544 cell lines, while synergy was demonstrated in all other
cell lines (Supplemental Data Image 1). Four of the 9 double-
mutant cell lines with varied proliferation data by SRB (HCT116,
DLD-1, LS174T and LS180) were selected for further in vitro
evaluation.
Effects on Downstream Effectors of MEK and Aurora
A Kinase Inhibition in Double-mutant Colorectal
Cancer Cell Lines
Immunoblotting for total and phosphorylated ERK was
performed to evaluate MAPK pathway inhibition. As expected,
cell lines treated with TAK-733 as a single agent demonstrated a
clear decrease in phosphorylated ERK, which was maintained in
the combination (Figure 2) (von Euw et al., 2012). Interestingly,
in the LS180 cell line, an increase in phosphorylated AKT
was observed following treatment with TAK-733 that was not
observed in the other cell lines (Figure 2). Alisertib did not affect
these MAPK pathway markers.
The effects of Aurora A kinase inhibition were also evaluated
by immunoblotting, with use of nocodazole to facilitate arrest
of cells in G2/M, the phase of the cell cycle during which
Aurora A protein levels peak (Crosio et al., 2002). A decrease in
phosphorylated Aurora A was observed in HCT116 and DLD1
cell lines, although this decrease was not as pronounced in
the LS174T and LS180 cell lines (Supplemental Data Image 2).
Levels of phosphorylated histone H3 (pHH3) were relatively
stable in the treated HCT116, DLD-1, and LS174T cell lines. Of
note, pHH3 did appear to decrease in LS180 when treated at
0.03125 and 0.0625µM concentrations of alisertib as compared
to nocodazole-only treated cells.
Effects of Alisertib and TAK-733 on the Cell Cycle in
Double-mutant Cell Lines
The four selected CRC cell lines were evaluated for effects on cell
cycle by flow cytometry following treatment with single-agent
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FIGURE 1 | Proliferative effects of alisertib and TAK-733 alone and
in combination on colorectal cancer cell lines. (A) Combination Index
values for colorectal cancer cell lines of 4 distinct molecular subtypes
treated with alisertib (0.05µM, 0.1µM, and 0.2µM) and TAK-733
(0.06µM, 0.125µM, and 0.25µM). Most pronounced synergy is observed
in cell lines with KRAS and PIK3CA mutations, with a mean CI value of
0.55 ± 0.05, as compared to 0.876 ± 0.077 in the BRAF MT model,
0.89 ± 0.097 in the KRAS WT/PIK3CA WT model, and 53.68 ± 5.48 in
the KRAS MT/PIK3CA WT model. (B) Mutation profile of 9 selected
colorectal cancer cell lines with KRAS and PIK3CA mutations. (C)
Calculated half maximal inhibitory concentration (IC50) values for KRAS
and PIK3CA double-mutant cell lines treated with single-agent alisertib
(doses ranging from 0.03125 to 0.5µM) and TAK-733 (ranging from 0.06
to 0.25µM). (D) Fraction of growth inhibition in double-mutant cell lines
exposed to three different dose levels of alisertib and TAK-733 in
combination by SRB at 72 h: 1 = alisertib 0.03125µM and TAK-733
0.06µM, 2 = alisertib 0.125µM and TAK-733 0.125µM, and 3 =
alisertib 0.5µM and TAK-733 0.25µM.
alisertib, single-agent TAK-733, or a combination (Figure 3).
Prior studies have demonstrated a delay in G2/M progression
associated with Aurora A kinase inhibition of alisertib (Manfredi
et al., 2011), while MEK inhibition by TAK-733 has been shown
to produce cell cycle arrest in G1 (von Euw et al., 2012). Similar
to other reports, we demonstrated a robust G2/M delay in
HCT116 and DLD-1 following treatment with alisertib, which
was largely conserved with the drug combination. However,
this G2/M delay was not as significant in LS174T and LS180,
indicating a differential effect on cell cycle activity in these cell
lines.
To confirm these findings, additional markers of cell cycle
progression were evaluated by immunoblotting (Figure 3). An
increase in total cyclin B1, a mediator of mitotic entry,
was observed in HCT116, DLD-1, and LS180 cells following
treatment with alisertib alone and in combination with TAK-733,
though no change in cyclin B1 was observed in LS174T cells. In
normal human cells, levels of total cyclin B1 increase through
late G2 phase, and decrease throughout mitosis (Lindqvist et al.,
2009).
Apoptosis in Colorectal Cancer Cell Lines Treated
with Alisertib and TAK-733
To evaluate the effects of these drugs on apoptosis, a caspase
3/7 assay was performed at 24, 48, and 72 h (Supplemental
Data Image 3A). Activity of caspase 3/7 increased in DLD-
1 (representative of a cell line with more robust G2/M delay
per data above) with alisertib alone at 0.125 and 0.5µM
concentrations, and in combination with TAK-733 0.0625µM at
48 h. At 72 h, caspase activity in the cells treated with all three
doses of alisertib (0.03125, 0.125, and 0.5µM) in combination
with TAK-733 (0.0625, 0.125, and 0.25µM) increased above that
in cells treated with alisertib alone. No significant increase in
caspase 3/7 was observed in LS174T (representing a cell line with
less pronounced G2/M delay) at both 48 and 72-h time points.
Immunoblotting for cleaved PARP as an additional apoptotic
marker also demonstrated distinct responses in the DLD-1
vs. LS174T cell lines when treated with alisertib alone and
in combination for 24 h (Supplemental Data Image 3B). A
significant increase in cleaved PARP was demonstrated in the
DLD-1 cell line treated with alisertib, which further increased
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FIGURE 2 | Effect of MEK inhibition by TAK-733 alone and in
combination with alisertib on downstream effectors. Effectors of the
mitogen activated protein kinase (MAPK) and phosphatidylinositide 3-kinase
(PI3K) pathways were evaluated at 24 h. Phosphorylated ERK decreases in
all double-mutant CRC cell lines when treated with TAK-733 alone or in
combination with alisertib.
when this drug was combined with TAK-733. No cleaved PARP
was observed in the LS174T cell line when treated with alisertib
or the drug combination.
To further evaluate the mechanisms underlying the apoptotic
activities documented above, the tumor suppressor protein
p53 and its homolog p73—both generally associated with pro-
apoptotic activity (Melino et al., 2002; Moll et al., 2005)—as well
as p21, a Cdk inhibitor and downstream effector of p53, were
evaluated by immunoblotting (Figure 4). Again using the same
cell lines to comparemodels in which treatment with alisertib and
TAK-733 produced differing apoptotic effects, p53 was noted to
increase upon treatment with alisertib alone and in combination
with TAK-733 in the p53 mutant cell line DLD-1 at both 24 and
72 h. However, in the p53 wild type cell line LS174T, a slight
increase in p53 was observed at 72 but not at 24 h. Similarly,
p21 increased slightly in the alisertib-treated DLD-1 cells at 24 h,
though higher levels of p21 are present and relatively stable in
both treated and untreated LS174T cells at this time point. At
72 h, p21 appears to increase in the DLD-1 cells treated with
alisertib alone, while a modest increase is seen in LS174T cells
treated with the drug alone and in combination. No difference
was observed in levels of p73 regardless of treatment.
In vivo Effects of Aurora A Kinase and MEK
Inhibitors
In vivo Modeling to Assess Combination Effects in
Colorectal Cancer Cell Line Xenografts
To further evaluate the efficacy of the combination of alisertib
and TAK-733 in vivo, colorectal cancer cell line xenograft
experiments were performed. Two double-mutant cell line
xenografts (HCT116 and HCT15), and one BRAF mutant
(COLO741) were treated with alisertib and TAK-733 alone and
in combination. Each tumor was modeled individually, and
the mean of each individual fit is presented in Supplemental
Data Image 4A (Bradshaw-Pierce et al., 2013). Based on this
modeling, a mathematical assessment of synergistic, additive, or
antagonistic response to combination therapy with alisertib and
TAK-733 could be assessed. According to the mathematical term
(ψ) identified for every individual tumor for each model (see
Supplemental Data Sheet 1), an additive to synergistic response
to combination therapy was seen in the double-mutant HCT116
xenograft (average ψ = 1.44 ± 0.42), while a generally additive
response was noted in the double-mutant xenograft HCT15
(average ψ = 1.15 ± 0.37), and less than additive effects were
observed in the BRAFmutant COLO741 xenograft (averageψ =
0.71± 0.54) (Supplemental Data Image 4B).
Anti-tumor Activity of Alisertib and Trametinib in
Patient Derived Colorectal Xenograft Models
In order to provide the most clinically relevant assessment of
the combination of an Aurora A kinase and MEK inhibitor
in human tumor xenograft experiments, the MEK inhibitor
trametinib, which is approved for clinical use in BRAF-mutated,
advanced melanoma (Flaherty et al., 2012), was substituted
for TAK-733. Thirty colorectal cancer cell lines treated with
trametinib demonstrated a pattern of anti-proliferative activity
similar to that of TAK-733, indicating similar spectrum of
activity. This panel included eight of the nine double-mutant cell
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FIGURE 3 | Effect of alisertib and TAK-733 alone and in combination
on the cell cycle. Left: Cell cycle analysis of double-mutant CRC cell lines
upon exposure to alisertib and TAK-733 as single agents and in combination
for 24 h by flow cytometry, with more pronounced G2/M delay observed in
HCT116 and DLD-1 cell lines. Right: Immunoblotting for cyclin B1 and
phosphorylated cyclin B1 in double-mutant cell lines, with increase in cyclin
B1 observed upon exposure to alisertib alone for 24 h, and further when
combined with TAK-733 for 24 h, in 3 of 4 cell lines.
lines evaluated by proliferation assays as described above (data
not shown).
Two human tumor xenograft models with known KRAS
and PIK3CA mutations (CUCRC40 and CUCRC98) were
treated with alisertib and trametinib as single agents and
in combination at various doses: alisertib 10 and 20mg/kg
and trametinib 0.5 and 1.5mg/kg. In the CUCRC40 model
(Figures 5A–D), more pronounced tumor growth inhibition
was observed with combination therapy at doses of alisertib
20mg/kg and trametinib 0.5mg/kg (Figure 5C). A statistically
significant difference was documented between the control and
combination arms (p < 0.001), as well as single-agent trametinib
and combination arms (p < 0.05), at these doses according
to a non-parametric Kruskal-Wallis test with Dunn’s post-test.
When comparing treatment arms using an unpaired t-test, a
statistically significant difference between combination therapy
and each single agent treatment was observed at these doses, as
well as at doses of alisertib 20mg/kg and trametinib 1.5mg/kg
(Figure 5D). Similar results were not observed at the lower
(10mg/kg) dose of alisertib.
This enhanced combination effect was not as pronounced in
the CUCRC98 explant model (Supplemental Data Images 5A–
D), where a statistically significant difference was only observed
between the control and combination arms at the alisertib
20mg/kg and trametinib 1.5mg/kg dose (Supplemental Data
Image 5D) according to a non-parametric Kruskal-Wallis test
with Dunn’s post-test (p < 0.05). This finding was confirmed
by unpaired t-test (p = 0.0462).
Discussion
Retrospective data demonstrating a lack of response of patients
with KRAS exon 2 mutant, and now extended RAS mutant,
metastatic colorectal cancer to anti-EGFR therapy has changed
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FIGURE 4 | Effect of alisertib and TAK-733 alone and in combination
on p53, p73, and p21. Evaluation was performed in p53 mutant (DLD-1)
and wild type (LS174T) CRC cell lines at 24 and 72 h, with a more robust
increase in p53 observed at both 24 and 72 h in the p53 mutant DLD-1 cell
line. An increase in p21 is demonstrated in the DLD-1 cells exposed to
alisertib alone, with no change noted in the LS174T cell line.
the focus of colorectal cancer treatment to one of personalized
cancer care. Unfortunately, before these differential responses
to therapy were realized, thousands of colorectal cancer
patients with KRAS exon 2 and other clinically significant
RAS mutations had been treated with an agent that is
now known to provide them no benefit. This evolution
of EGFR inhibitor therapy in the treatment of metastatic
colorectal cancer has revealed the importance of identifying
patient populations more likely to respond to novel biologic
targeted agents in the early stages of their development, so
as to avoid unnecessary exposure of patients to ineffective
therapies. In line with this goal, the purpose of this study
was to identify a molecular subtype of colorectal cancer that
might be more likely to respond to the novel combination
of a MEK and Aurora A kinase inhibitor in pre-clinical
models.
The first phase of this goal was achieved in the identification
of greater synergy of Aurora A kinase inhibitor alisertib and
MEK inhibitor TAK-733 in CRCmodels with concomitant KRAS
and PIK3CA mutations. Within this double-mutant subgroup,
attempts were made to further define a population in which
greater synergistic combination effects, rather than additive or
antagonistic effects, were consistently demonstrated, as has been
achieved in previous work by our group (Spreafico et al., 2013).
However, despite evaluation by a variety of methods, no clear
subpopulation of double-mutant colorectal cancer cell lines
emerged as one associated with a more synergistic response to
combination therapy.
Though reliable differences in synergistic drug effects of
alisertib and TAK-733 in the double-mutant colorectal cancer cell
lines were not observed, additional attempts at better defining a
molecular subtype most likely to respond to therapy with this
drug combination did provide interesting results. Of greatest
interest are the differing effects of the drugs alone and in
combination on cell cycle progression. This was demonstrated in
cell cycle analysis of double-mutant cell lines by flow cytometry,
where a more pronounced G2/M delay was identified in the
HCT116 and DLD-1 cells treated with alisertib alone and in
combination with TAK-733 as compared to the LS174T and
LS180 cells.
Furthermore, a difference in levels of cyclin B1, an indicator
of the outcome of cell cycle delay induced by Aurora A kinase
inhibitor alisertib, was also observed in double-mutant colorectal
cancer cell lines. As has been previously described, when cyclin
B1 levels decline to the point that mitotic arrest can no longer
be sustained, mitotic slippage (and potentially cell survival),
rather than cell death, can occur if apoptotic pathways have not
had sufficient time for activation (Hilton and Shapiro, 2014).
However, if cyclin B1 levels can be sustained long enough, cells
in which Aurora A kinase is inhibited will proceed to apoptosis.
This concept is of interest to our data given the increase in cyclin
B1 noted in 3 out of 4 cell lines treated with alisertib alone. Of
even greater interest is the further increase in cyclin B1 levels
(most clearly in the HCT116 cell line) when TAK-733 is added
to alisertib as combination therapy. This finding may suggest a
mechanism by which the combination of targeted agents might
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FIGURE 5 | Anti-tumor activity of alisertib and trametinib alone
and in combination in CRC patient-derived tumor xenograft
model CUCRC40 at various doses. (A) Alisertib 10mg/kg,
trametinib 0.5mg/kg, (B) alisertib 10mg/kg, trametinib 1.5mg/kg, (C)
alisertib 20mg/kg, trametinib 0.5mg/kg, (D) alisertib 20mg/kg,
trametinib 1.5mg/kg. Most notable combination effect was observed
at doses of alisertib 20mg/kg with trametinib 0.5 or 1.5mg/kg, with
a statistically significant difference between single-agent and
combination treatment effect documented according to an unpaired
t-test in these models.
better facilitate apoptosis and avoid mitotic slippage reflected by
a more robust increase in cyclin B1.
Though this suggestion provides one possible mechanism
through which an Aurora A kinase inhibitor and MEK inhibitor
may act synergistically in select colorectal cancer models, there
is also data indicating that MEK inhibition induces degradation
of c-Myc (Duncan et al., 2012). Though demonstrated in breast
cancer models, this concept has important implications given
a potential relationship between Aurora A kinase and Myc,
as demonstrated in various Myc-driven malignancies including
hepatocellular carcinoma and B-cell lymphomas (Den Hollander
et al., 2010; Lu et al., 2014). In both tumor types, Myc has
been found to induce Aurora A kinase, and thus it may
be hypothesized that the more synergistic combination effects
demonstrated in select CRC models could be due to MEK
inhibitor mediated degradation of c-Myc leading to more robust
effects on Aurora A.
The above-described in vitro data were further elucidated in
vivo, using cell line and patient-derived xenograft models. Results
from synergy modeling of cell line xenografts demonstrating a
trend to a more synergistic response to combination therapy
with alisertib and TAK-733 in one of the double-mutant models
(HCT116), as compared to an additive response in the other
(HCT15), is in keeping with the concept of a subpopulation
within the double-mutant subgroup in which more synergistic
combination effects occur, though the effect size was small. In
the CUCRC40 double-mutant patient-derived tumor xenograft
model, the combination of alisertib and trametinib with greatest
anti-tumor activity was achieved with a higher dose of alisertib
(20mg/kg), suggesting cell cycle inhibition by the Aurora
A kinase inhibitor is an important driver of tumor growth
inhibition. However, the same was not observed in treatment of
the CUCRC98 xenograft model, where a significant increase in
tumor growth inhibition in response to combined therapy was
not observed at any dose. This pattern documented across in vivo
models indicates that, similar to patients (Amado et al., 2008;
Karapetis et al., 2008; Kopetz et al., 2010), the double-mutant
genotype does not identify a consistently responsive subset of
CRC. It is important to note that the clinically approved MEK
inhibitor trametinib was substituted for TAK-733 in these in vivo
studies, though in vitro data indicating similar anti-proliferative
activity across a range of CRC cell lines suggests this change did
not have a drastic impact.
An additional finding of interest in our work is related
to the p53 protein. The interaction between p53 and Aurora
kinases are complex, and it is currently believed that Aurora A
phosphorylates and thus down regulates p53 and its associated
apoptotic activity (Katayama et al., 2004). In turn, inhibition
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of Aurora A with drugs such as alisertib leads to activation
of p53 and its downstream effectors. Interestingly, loss of p53
is also thought to increase sensitivity to both Aurora A and
Aurora B kinase inhibition (Marxer et al., 2014). Our assessment
of p53 by immunoblotting in double-mutant colorectal cancer
cell lines demonstrated an increase in p53 upon treatment with
alisertib alone and in combination with TAK-733 at both 24 and
72 h in a p53 mutant model, DLD-1. Interestingly, in the p53
wild type cell line LS174T, p53 was not up-regulated after 24 h,
though it was when treated with alisertib as a single agent and in
combination with TAK-733 at the 72 h timepoint. These findings
are consistent with prior data showing that unlike wild type p53,
mutant p53 is not down-regulated by Aurora A kinase (Katayama
et al., 2004). This explains the presence of p53 protein at both
early and late time points in the p53 mutant cell line DLD-1 at
baseline, as well as the more significant increase of the protein
upon treatment with alisertib alone or in combination with TAK-
733. Wild type p53 is typically undetectable by immunoblot due
to its down-regulation through MDM-2. However, we observed
an increased level of p53 protein in response to treatment
with alisertib in the p53 WT cell line LS174T, indicating a
DNA damage response as a result of prolonged cell cycle
delay.
As the downstream transcriptional target of p53, p21 does
slightly increase, though this appears to occur at a lesser degree
in the p53 mutant DLD-1 cell line when alisertib is combined
with TAK-733. This is of particular interest given the increased
understanding of the duality of the p21 protein, which is
currently believed to contribute to both cell cycle arrest and anti-
apoptotic processes (Gartel and Tyner, 2002). The findings of a
less robust increase in p21 with an equivalent increase in p53
in cells treated with combination therapy vs. alisertib alone may
indicate a mechanism by which the MEK inhibitor facilitates the
pro-apoptotic effects of p53 induction through Aurora A kinase
inhibition by decreasing the anti-apoptotic effects of p21. This
concept is further supported by the increased apoptotic activity
demonstrated in the p53 mutant cell line DLD-1 when treated
with the combination of alisertib and TAK-733 as compared to
the p53 wild type cell line LS174T.
Also of interest is the lack of increase in p21 noted in the
p53 wild type LS174T cell line upon exposure to alisertib alone
and in combination, as compared to the p53 mutant DLD-
1 cell line. When this finding is considered in the context
of a recently identified transcription factor (TCF3/E2A) that
increases expression of p21 while decreasing that of p53 target
PUMA, a mediator of p53-induced apoptosis, (Andrysik et al.,
2013) it seems possible that there may be an imbalance present
in some molecular subtypes of CRC toward p21 activation and
cell cycle arrest vs. PUMA activation and apoptosis. It is thus
possible that differing levels of p21 in these cell lines indicate a
trend toward one of these two subtypes. This concept is in line
with findings in our work that demonstrate a more pronounced
G2/M delay in the DLD-1 cells upon exposure to alisertib alone
and in combination with TAK-733 that mirrors the increase in
p21, while in LS174T cells where less pronounced G2/M delay
was documented, no change in p21 was identified. This data may
indicate that DLD-1 and LS174T cell lines do in fact represent
distinct molecular subtypes of CRC.
Our data represents the first evaluation of the combination
of an Aurora A kinase and MEK inhibitor in colorectal cancer
models. Unfortunately, as has been a common theme in clinical
studies evaluating targeted agents for the treatment of metastatic
colorectal cancer, we were unable to clearly identify a subset
of CRC that is more (or more consistently) responsive to the
combination of a MEK and Aurora A kinase inhibitor. Though
greater elucidation of specific biomarkers predictive of response
to such combination therapy was not achieved in our work,
our efforts do suggest that degree of G2/M cell cycle delay, p53
mutation status, and possibly p21 levels, may affect outcomes of
treatment with the drug combination on the cellular level, and
provide areas of further investigation for pre-clinical and clinical
studies alike. Moving forward, further development of predictive
biomarkers will be key in determining the clinical applicability of
this drug combination.
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